FDA wants restrictions on bone meds with calcitonin; Arena says DEA's not finished with Belviq;

@FiercePharma: Merck CEO's biggest accomplishment so far? Standing firm on R&D spending as $MRK got pounded, he tells AP: Report | Follow @FiercePharma

@EricPFierce: Happy anniversary, Bayer. A year after India granted first compulsory license for Nexavar, board rejects appeal. News | Follow @EricPFierce

> FDA reviewers highlighted a "plausible" risk of cancer with bone drugs containing calcitonin salmon and recommended their use be restricted to exclude osteoporosis patients. Report

> Arena Pharmaceuticals ($ARNA) said the Drug Enforcement Administration hasn't yet finalized the controlled substances designation on its yet-to-be-launched obesity drug Belviq. Report

> Elan ($ELN) will let stockholders share in the royalties from its multiple sclerosis drug Tysabri in an attempt to fend off a $6.5 billion buyout bid from RP Management. Report

> Private equity firm Warburg Pincus tapped a group of investment bankers to lead a Bausch + Lomb IPO that would raise as much as $1.5 billion. Report

> In the wake of safety scandals, Chinese officials have proposed a new, stronger agency to oversee the food and drug industries. Report

> Boehringer Ingelheim has teamed up with the online community PatientsLikeMe to help patients with idiopathic pulmonary fibrosis to monitor their health and connect with other patients. Report

Medical Device News

 @FierceMedDev: Special Report: Devicemakers plot paths out of CRM funk. Feature | Follow @FierceMedDev

 @MarkHFierce: Toshiba's medical equipment division is expanding in South Korea. Release | Follow @MarkHFierce

 @DamianFierce: Parexel says it's got its M&A eye on the Middle East and some small tech companies this year. Report | Follow @DamianFierce

> Stryker closes $764M deal for Chinese ortho giant. Article

> Toshiba Medical rolls out South Korean subsidiary. Story

Biotech News

 @FierceBiotech: Popular this weekend: Celgene's blockbuster dreams fade as apremilast PhIII fails to excite. Story | Follow @FierceBiotech

@JohnCFierce: Doctors declare "functional cure" of an infant infected with HIV--A first for an infant. More | Follow @JohnCFierce

@RyanMFierce: J&J backs startup effort tackling Big Data-driven disease models. More from FierceBiotechIT.com | Follow @RyanMFierce

> Merck KGaA fashions its 6th biotech from Serono R&D wreckage. News

> Elan woos investors with a special dividend plan for Tysabri. Item

> Novartis CEO Jimenez focuses R&D on the new blockbuster paradigm. Report

> Celgene's blockbuster dreams fade as apremalist PhIII fails to excite. Story

CRO News

> Trial sites say Biogen, Forest, Bayer are top sponsors. Item

> Covance allies with M2Gen for personalized medicine, cancer trials. News

> Particle Sciences teams with Chinese CRO on solubility. More

> Capsugel bets on drug delivery with Encap buy. Report

> Synteract goes global with Harrison buyout. Article

Biotech IT News

> Could playing mobile phone games help advance cancer cures? More

> GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner

> Accelrys marks Q4 growth as buyouts weigh on bottom line. Report

> Biocon chief prescribes new tech, analytics to treat R&D woes in pharma. Story

> What Facebook and Google billionaires could do for overlooked biotech brains. Item

And Finally... Doctors say they've cured an infant born with HIV by giving her a cocktail of available drugs shortly after birth. Report

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.